NDA 220149 · Janssen Biotech
Icotyde
Icotrokinra Hydrochloride · Oral
NovelPriority reviewCDER novel approval, Mar 17, 2026: To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy
Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Mar 17, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
4 Phase 3, 1 recruiting
FAERS reports
428
66 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 17, 2026.
ICOTYDE is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is an interleukin-23 (IL-23) receptor antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ( 1 )
Mechanism: Icotrokinra is a peptide that selectively binds to the IL-23 receptor (IL-23R) with a dissociation constant of 7 pM and antagonizes the binding of IL-23. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Icotrokinra inhibits the IL-23/IL-23R-dependent release of proinflammatory cytokines.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 17, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelMedication Guide
1 products under this application
- ICOTYDE · ICOTROKINRA HYDROCHLORIDE EQ 200MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Icotrokinra" as an intervention, any sponsor and status, largest first.
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07196722 · 1,092 participants (planned) · Start Oct 3, 2025 · Primary completion Sep 19, 2028
Drug: Icotrokinra; Placebo · For: Crohn Disease
Sites: Chandler, Arizona; Litchfield Park, Arizona; Scottsdale, Arizona · 395 sites in all
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07196748 · 896 participants · Start Oct 1, 2025 · Primary completion Jan 14, 2028
Drug: Icotrokinra; Placebo · For: Colitis, Ulcerative
Sites: Chandler, Arizona; Litchfield Park, Arizona; Scottsdale, Arizona · 402 sites in all
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06807424 · 813 participants · Start Jan 9, 2025 · Primary completion Feb 10, 2027
Drug: Icotrokinra; Placebo · For: Arthritis, Psoriatic
Sites: Glendale, Arizona; Mesa, Arizona; Jonesboro, Arkansas · 236 sites in all
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06878404 · 552 participants · Start Feb 21, 2025 · Primary completion May 25, 2026
Drug: Icotrokinra; Placebo and 1 more · For: Arthritis, Psoriatic
Sites: Jonesboro, Arkansas; DeBary, Florida; Plantation, Florida · 155 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache46
- nausea38
- product dose omission issue30
- fatigue27
- rash24
- drug ineffective23
- psoriasis19
- off label use15
- pain15
- diarrhoea14
- cough13
- abdominal discomfort12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 428 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.
Bissonnette R, Soung J, Hebert AA, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Gold LS, Armstrong AW, Bissonnette R, et al. · Lancet 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites.
Gooderham M, Lain E, Bissonnette R, et al. · NEJM Evid 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.
Strawn D, Krueger JG, Bissonnette R, et al. · JCI Insight 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.
Warren RB, Gooderham M, Lain E, et al. · J Eur Acad Dermatol Venereol 2026 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis.
Advani S, Raja A, Giraldo T, et al. · Clin Exp Dermatol 2026 · Systematic Review, Meta-Analysis
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.